Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

Phase 2

Completed

• Conditions: Asthma, Bronchial; Bronchial Asthma

• Registration Number: NCT00189787
• Lead Sponsor: Astellas Pharma Inc

Brief Summary

This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

Detailed Description

Not available

Study Timeline

• Primary Completion: 2005-08
• Study Completion: 2005-08
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-19
• Status Verified: 2008-04
• Last Update Submitted: 2008-04-15
• Last Update Posted: 2008-04-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 370

Inclusion Criteria

• Diagnosis of asthma
• Patients treated with inhaled corticosteroid
• FEV1 (forced expiratory volume in 1 second)>60% to 80%

Read More

Exclusion Criteria

• Respiratory infection within 2 weeks
• Asthma exacerbation within 90 days

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL